Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

1663 results about "Effector" patented technology

In biochemistry, an effector molecule is usually a small molecule that selectively binds to a protein and regulates its biological activity. In this manner, effector molecules act as ligands that can increase or decrease enzyme activity, gene expression, or cell signaling. Effector molecules can also directly regulate the activity of some mRNA molecules (riboswitches).

Bicyclic peptide ligands specific for nectin-4

The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and / or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.
Owner:BICYCLETX LTD

Novel type of crispr / cas system

The technology described herein relates to new CRISPR / Cas systems and components thereof, vectors, proteins, fusion proteins, ribonucleoprotein complexes and methods of using the new system and components. The new system can be used in CRISPRi applications and can be fused to any number of effector domain modalities, such as nucleases, base editors, prime editors and the like to perform various DNA modifications.
Owner:SNIPR BIOME APS

Antibody variants and uses thereof

Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.
Owner:GENMAB BV

Novel CRISPR-Casdelta enzymes and systems

The invention relates to the field of nucleic acid editing, in particular to the technical field of regularly clustered interval short palindromic repeat (CRISPR). In particular, the present invention relates to Cas effector proteins, fusion proteins comprising such proteins, and nucleic acid molecules encoding them. The invention also relates to complexes and compositions for nucleic acid editing (e.g., gene or genome editing) comprising the proteins or fusion proteins of the invention, or nucleic acid molecules encoding them. The invention also relates to methods for nucleic acid editing (e.g., gene or genome editing) using the proteins or fusion proteins comprising the invention.
Owner:CHINA AGRI UNIV

Nucleobase editors comprising geocas9 and uses thereof

Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids or the modification of nucleic acids or proteins, including editing a single site within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins of nucleic acid programmable DNA binding proteins e.g., GeoCas9 or variants thereof, and effector domains, e.g., deaminase domains, are provided. In some embodiments, methods for targeted nucleic acid editing or protein modification are provided. In some embodiments, reagents and kits for the generation of targeted nucleic acid editing proteins, e.g., fusion proteins of a GeoCas9 and effector domains, are provided.
Owner:THE BROAD INST INC

Antibody variants and uses thereof

Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.
Owner:GENMAB BV

Base editing system based on TraC effect protein and application thereof

The invention belongs to the field of gene engineering, and relates to a DNA binding protein based on TraC effect protein, a fusion protein with a cytosine / adenine base editing function, an editing system and nucleic acid molecules or constructs for encoding the DNA binding protein and the fusion protein. The invention also relates to complexes and kits for gene editing comprising the fusion proteins of the invention or the nucleic acid molecules encoding them. The base editing tool disclosed by the invention can realize efficient, accurate and safe base editing in cells of various eukaryotes such as animals and plants. The unique characteristics of the base editing tool enrich the types of existing base editing tools, and the base editing tool has wide application prospects.
Owner:BEIJING QI BIODESIGN BIOTECHNOLOGY CO LTD

Novel CRISPR / Cas system

The technology described herein relates to novel CRISPR / Cas systems and components thereof, vectors, proteins, fusion proteins, ribonucleoprotein complexes and methods of using the novel systems and components. The new system can be used in CRIS PRi applications and can be fused with any number of effector domain patterns, such as nuclease, base editor, leader editor, and the like, to conduct a variety of DNA modifications.
Owner:SNIPR BIOME APS

Tilletia controversa Kuhn effect protein g16561 and application thereof

The invention belongs to the field of prevention and treatment of tilletia controversa Kuhn, and particularly relates to a tilletia controversa Kuhn effect protein g16561 and application thereof. An amino acid sequence of the Tilletia controversa Kuhn effect protein is shown as SEQ ID NO: 2. The effect protein plays an important role in the process of inhibiting plant defense reaction, and has an interaction relationship with a wheat protein in the process of infecting wheat by Tilletia controversa Kuhn. According to the invention, the pathogenesis of Tilletia controversa Kuhn can be deeply researched, and the excavation of wheat disease-resistant genes and the cultivation of wheat disease-resistant varieties can be promoted.
Owner:SANYA NATIONAL INSTITUTE OF SOUTHERN BREEDING CHINESE ACADEMY OF AGRICULTURAL SCIENCES +2

Method for improving cordycepin synthesized by saccharomyces cerevisiae and saccharomyces cerevisiae engineering bacteria

The invention relates to the technical field of microbial genetic engineering, in particular to a method for improving cordycepin synthesized by saccharomyces cerevisiae and saccharomyces cerevisiae engineering bacteria. According to the invention, codon-optimized 2 '-carbonyl-3'-deoxyadenosine reductase gene and 3 '-adenosine monophosphate phosphohydrolase gene from cordyceps militaris are expressed by using plasmids, and then the plasmids are transformed into host cells to obtain the saccharomyces cerevisiae engineering bacteria. And inoculating a seed solution obtained by seed culture of the activated saccharomyces cerevisiae engineering bacteria into a fermentation culture medium containing a metabolic effector, and carrying out fermentation culture to synthesize cordycepin. Metabolic effectors (Cu < 2 + >, Fe < 2 + >, Mg < 2 + >, Zn < 2 + >, citric acid, cysteine, aspartic acid, glycine, VB1 and tea polyphenol) are added into a fermentation culture medium strain, and the variety and concentration of the metabolic effectors are optimized, so that the yield and synthesis efficiency of cordycepin are remarkably improved. By using the combination of the strain obtained by the invention and the optimal effector, the yield of cordycepin in a fermentation tank reaches 2.9 g / L.
Owner:NANJING TECH UNIV

Heterobifunctional compounds and their use in treating disease

The invention provides heterobifunctional compounds comprising an effector protein binding moiety selected from GSPT1, Cyclin K, RBM23, RBM39, IKZF1, IKZF3, PLK1, CDK4 or CK1alpha which is linked to a moiety that binds to a target protein selected from KRAS, HER2, EGFR, androgen receptor protein, estrogen receptor protein, ALK, IDH1, FLT3, FGFR1, FGFR4, FGFR2, FGFR3, ERK1, ERK2, FGR, HER3 or HER4. Pharmaceutical compositions and their use in treating disease, such as cancer, are also disclosed.
Owner:HALDA THERAPEUTICS OPCO INC

CAS9 proteins including ligand-dependent inteins

Some aspects of this disclosure provide compositions, methods, systems, and kits for controlling the activity of RNA-programmable endonucleases, such as Cas9, or for controlling the activity of proteins comprising a Cas9 variant fused to a functional effector domain, such as a nuclease, nickase, recombinase, deaminase, transcriptional activator, transcriptional repressor, or epigenetic modifying domain. For example, the inventive proteins provided comprise a ligand-dependent intein, the presence of which inhibits one or more activities of the protein (e.g., gRNA binding, enzymatic activity, target DNA binding). The binding of a ligand to the intein results in self-excision of the intein, restoring the activity of the protein.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Conjugates of saponin and antisense oligonucleotides for use in the treatment of neurodegenerative diseases

PCT designated stage expiredWO2024261042A1Senses disorderNervous disorderBiological targetNeural Canal
The present invention relates to the fields of therapy and drug delivery. More specifically, disclosed herein are therapeutic methods and pharmaceutical compositions for treating disorders of blood-tissue barrier-shielded organs that harbour substantive populations of post-mitotic neurons, such as the organs derived from neural tube that include the central nervous system and the eye. The disclosed methods and compositions involve localised administration into such organs of an effector component that targets an intracellular biological target, in combination with a saponin component that enhances effective uptake of the effector component into the cells and / or that enhances effective routing of the effector component inside the cells where the biological target is present. For example, the effector component can be an oligonucleotide therapeutic that is targeting a gene product associated with the disorder of the CNS and / or of the eye. Due to cellular uptake-stimulating and / or endosomal escape enhancing effects of the saponin component, the presented herein neuropharmaceutical and ophthalmic compositions for the localised administration into the CNS and / or into the eye, respectively, can be formulated with lower concentrations of the effector component and / or at lower volumes, which confers safety-benefits to the neurons and to the comfort of the patient.
Owner:SAPREME TECH BV

Preparation and application of dsMpC002-coated ZIF-8 nano-composite

The invention relates to the technical field of biology, and particularly provides preparation and application of a dsMpC002-coated ZIF-8 nano complex. According to the invention, a green peach aphid effector dsMpC002 is taken as a target, a ZIF-8 delivery system of the green peach aphid effector dsMpC002 with a stable superexcellent target is constructed, and a dsMpC002-ZIF-8 nano-composite is prepared and obtained. By observing and analyzing the MpC002 gene expression quantity, the death rate and the single female farrowing quantity of the green peach aphid after the pepper variety DYJ sprayed with the dsMpC002-coated ZIF-8 nano-complex with different concentrations is fed, the control effect of the dsMpC002-coated ZIF-8 nano-complex on the green peach aphid is determined. And a new target technology and a new idea are provided for innovating an aphid control method.
Owner:SANYA RES INST OF CHINESE ACAD OF TROPICAL AGRI +1

Preparation method of PSR.Syn.CD19. BCMA CAR-T cell as well as cell and application of PSR.Syn.CD19. BCMA CAR-T cell

The invention provides a preparation method of a PSR.Syn.CD19. BCMA CAR-T cell as well as the cell and application of the PSR.Syn.CD19. BCMA CAR-T cell, the PSR.Syn.CD19. BCMA CAR-T cell is characterized in that after the CAR-T cell and a CD19 antigen positive tumor cell are co-incubated, the expression of an effector molecule BCMA-CAR can be induced, and if the tumor cell simultaneously expresses a BCMA antigen, the CAR-T cell capable of killing a tumor can be identified. Experimental results show that the cell prepared by the method can efficiently and specifically kill tumor cells, has a persistent killing effect and has a safety switch capable of starting a killing function. In addition, the tumor can be specifically killed, the cell proliferation rate is high, and the proliferation rate under the stimulation of tumor cells is higher than that of a PAN-T group.
Owner:GUANGDONG JUNHOU BIOMEDICAL CO LTD +1

Formulations for modulating MYC expression

The present disclosure relates to compositions and methods for reducing expression of MYC gene in a cell. In some embodiments, an expression repressor comprises a targeting moiety that binds a MYC promoter, anchor sequence, or super-enhancer. In some embodiments, the expression repressor comprises an effector moiety that represses transcription or methylates DNA. Systems comprising two expression repressors are also disclosed. The compositions can be used, for example, to treat cancers such as HCC.
Owner:ACUITAS THERAPEUTICS INC +1

Inhibitors of RAF kinases

Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Owner:PIERRE FABRE MEDICAMENT SAS

Compositions and methods for targeted epigenetic modification

Provided herein are compositions, systems, and methods comprising effector proteins, and uses thereof. These effector proteins may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure may leverage the activities of these effector proteins for the epigenetic modification of nucleic acids.
Owner:MAMMOTH BIOSCIENCES INC

Heterobifunctional compounds and their use in treating disease

The invention provides heterobifunctional compounds comprising an effector protein binding moiety selected from mTor, PLK1, CDKI, CDK2, CDK9, BRD4, AURKA, AURKB, MEK, Src, c-KIT, KIF11, HSP90, tubulin, proteasome, topoisomerase or HD AC which is linked to a moiety that binds to a target protein selected from KRAS, HER2 or EGFR. Pharmaceutical compositions and their use in treating disease, such as cancer, are also disclosed.
Owner:HALDA THERAPEUTICS OPCO INC

Bicyclic peptide ligands specific for nectin-4

The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and / or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.
Owner:BICYCLETX LTD

Antibody-oligonucleotide conjugate

The invention relates to a ligand-effector moiety provided with at least one saponin and antibody-effector moiety provided with at least one saponin. An aspect of the invention is a composition comprising the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin of the invention. The invention also relates to an antibody-drug conjugate comprising covalently linked saponin and to an antibody-oligonucleotide conjugate comprising covalently linked saponin. An aspect of the invention relates to a pharmaceutical composition comprising the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin of the invention, and optionally further comprising a pharmaceutically acceptable excipient. The invention also relates to the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin, for use as a medicament. The invention also relates to the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin of the invention for use in the treatment or prophylaxis of a cancer.
Owner:SAPREME TECH BV

Compositions and methods for modifying antibody effector functions

Feline, canine, and equine antibody variants and uses thereof, as well as compositions and methods for improving therapeutic monoclonal antibodies by modulating immune effector functions and antibody variants using those methods and compositions.
Owner:ZOETIS SERVICES LLC

Therapeutic circular DNA forms

The disclosure provides, for example, double stranded DNA (dsDNA) molecules comprising one or more chemically modified nucleobases. In some embodiments, the dsDNA molecule is circular and comprises a first strand and a second strand, wherein the first strand comprises one or more chemically modified nucleobases, and the second strand is free of chemically modified nucleobases. In some embodiments, the dsDNA molecule comprises a promoter sequence and an effector sequence that encodes an effector.
Owner:FLAGSHIP PIONEERING INNOVATIONS VII LLC

Method for improving NK (Natural Killer) cell effect function through targeted lactic acid modification

The invention belongs to the technical field of immunotherapy, and particularly relates to a method for improving NK cell functions by targeted inhibition of lactylation. The invention provides a method for improving functions of NK cells by targeted inhibition of lactylation, NK cell lactic acid transporters or modification enzymes in inhibition of the lactylation process are targeted, the modification enzymes are NK cell lactylation modification enzymes Writer or lactic acid coenzyme A synthetase, NK92MI lactylation modification is blocked, so that function depletion of the NK cells is reversed, and the NK cell function is improved. The function of the NK cell can be partially reversed by inhibiting the lactic acid modification, and the expression level of effector molecules of the NK92MI cell can be recovered.
Owner:SHANDONG UNIV

Plasmodiophora brassicae effector Pb78 and application thereof in prevention and treatment of Plasmodiophora brassicae infection

The invention provides a plasmodiophora brassicae effector Pb78, and the nucleotide sequence of the plasmodiophora brassicae effector Pb78 is shown The invention also provides an application of host-induced silencing of the plasmodiophora brassicae effector Pb78 in prevention and treatment of plasmodiophora brassicae infection, and also provides a plasmodiophora brassicae prevention and treatment liquid and a preparation method of the plasmodiophora brassicae prevention and treatment liquid. The invention verifies that host-induced plasmodiophora brassicae effector Pb78 silencing can effectively inhibit plasmodiophora brassicae infection and symptom formation of cruciferae plants. The preparation and the treatment method disclosed by the invention are suitable for various cruciferae crops and vegetables which can be infected by plasmodiophora brassicae, and are wider in applicability; the inhibition efficiency on clubroot is higher than that of medicament treatment, and the compound has the advantage of no pesticide residue and is high in safety; due to the adoption of a seed treatment mode, the method is particularly suitable for preventing and treating clubroot susceptible seedlings.
Owner:SICHUAN AGRI UNIV

Antibody variant combinations and uses thereof

Provided herein are combinations of first and second antibodies having modified Fc effector functions resulting from amino acid substitutions in the Fc region, the amino acid substitutions allow for co-dependent activation of effector functions such as CDC and / or ADCC. Also provided are combinations of first and second antibodies having agonistic activity or enhanced agonistic activity resulting from amino acid substitutions in the Fc region where the agonistic activity is co-dependent of both a first and second antibodies.
Owner:GENMAB BV

Engineered anti-IL-2 antibodies

Described herein are engineered anti-IL-2 antibodies with modified amino acid sequences. The engineered antibodies would confer modified receptor binding specificity to an IL-2-anti-IL2 antibody complex, inhibiting the binding of IL-2 to CD25. The engineered anti-IL-2 antibodies would facilitate expansion of subsets of effector immune cells and decrease undesirable effects caused by IL-2. Thus, the engineered anti-IL-2 antibodies would be useful in treating disease such as cancer and infection.
Owner:BIOLOJIC DESIGN LTD +1

Site-specific antibody-drug conjugation through glycoengineering

The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
Owner:GENZYME CORP